Tag Archives | ESMO 2011

2011 ESMO ESTRO ECCO Cancer Congress Prostate Cancer News

It’s exciting to see new products that make a difference to patients come to market. Multiple treatments improve overall survival (OS) in prostate cancer patients: docetaxel, cabazitaxel, sipuleucel-T, abiraterone acetate and now, radium-223 choloride. The phase 3 trial results for radium 223 chloride were presented at the 2011 European Multidisciplinary Cancer Congress (ESMO, ECCO, ESTRO) […]

Continue Reading

Follow coverage of 2011 Stockholm Cancer Congress #EMCC2011

The 2011 Stockholm Multidisciplinary Cancer Congress (more commonly known as ECCO 2011 or ESMO 2011) is underway in Stockholm, Sweden. Pieter Droppert (@3NT) will be writing on Biotech Strategy Blog from the meeting and in particular the new data on prostate cancer that will be presented, in particular the phase 3 Alpharadin ALSYMPCA trial data […]

Continue Reading

Conference Coverage: the week in review

Now that summer is officially over, the fall pharma/biotech conference season has started. You can find out details of the conferences Icarus Consultants will be attending by checking out our conference schedule. If you are interested in our meeting coverage services or a conference report, please contact us. This week, we followed two conferences remotely […]

Continue Reading

How to use an iPad for cancer conference coverage

Icarus Consultants’ social media and oncology expert, Sally Church, is also into business productivity. At the many cancer conferences she attends each year such as ASCO, ASH, AACR and the forthcoming ESMO/ECCO/ESTRO meeting in Stockholm, an iPad is now Sally’s preferred choice of device to travel with. How does Sally use an iPad to cover […]

Continue Reading

Custirsen OGX-011 a new Prostate Cancer treatment to watch

The prostate cancer market is dynamic, with a lot of news happening. One of the many new treatments in development worth watching is custirsen (OGX-011). Sally Church on Pharma Strategy Blog recently wrote about Custirsen from OncoGeneX. This drug inhibits the production of clusterin, a protein associated with the development of treatment resistance.  As Sally […]

Continue Reading

ECCO ESMO Stockholm Cancer Conference September 2011

Summer is almost over, and thoughts at Icarus Consultants are now turning to forthcoming medical meetings that we will be attending. Photo: Max Anderson We will be at ECCO 16 – ESMO 36 in Stockholm from September 23 – 27, 2011. The jointly organized multidisciplinary cancer congress of the European CanCer Organisation (ECCO ) and […]

Continue Reading